Physician profile
Junaid Sa Malik
NPI 1598859852
$428,647.94
in general payments reported to CMS, 2019-2025
62 companies · $73K in 2025
The $73K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $52K · 2021: $62K · 2022: $84K · 2023: $40K · 2024: $31K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $109K · Food and Beverage: $12K · Honoraria: $11K · Consulting Fee: $7,721 · Travel and Lodging: $5,530 · Education: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $108,777.68 |
| Food and Beverage | $11,573.32 |
| Honoraria | $11,000.00 |
| Consulting Fee | $7,721.25 |
| Travel and Lodging | $5,530.25 |
| Education | $328.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $176,563.33 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $113,401.48 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42,599.37 | 2019-2025 | Spiriva, Ofev, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $25,239.61 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $13,805.65 | 2019-2025 | |
| Lilly USA, LLC | $13,539.36 | 2025 | Zepbound |
| Verona Pharma, INC. | $12,020.14 | 2025 | Ohtuvayre |
| Resmed Corp | $6,430.20 | 2021-2023 | |
| Amgen INC. | $5,108.39 | 2019-2025 | Tezspire |
| Mylan Specialty L.P. | $3,754.88 | 2019-2023 | Yupelri |
| Medtronic, INC. | $1,859.62 | 2023-2025 | Illumisite |
| Inspire Medical Systems, INC. | $1,630.64 | 2019-2025 | Inspire |
| Zoll Respicardia, INC. | $1,600.99 | 2024-2025 | Remede System |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Intuitive Surgical, INC. | $1,152.63 | 2019-2023 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junaid Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.